UBS Group’s Oaktree Acquisition Corp III Life Sciences Warrant OACCW Stock Holding History

UBS Group’s Portfolio OACCW Stock Details OACCW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$528	Buy	561 +299	+114%	+$251	﹤0.01%	9814
2026 Q1	$138	Hold	262	–	–	﹤0.01%	10086
2025 Q4	$183	Sell	262 -1,046	-80%	-$873	﹤0.01%	10123
2025 Q3	$981	Sell	1,308 -24,144	-95%	-$19.5K	﹤0.01%	9469
2025 Q2	$22.3K	Sell	25,452 -5,578	-18%	-$4.3K	﹤0.01%	8361
2025 Q1	$23.3K	Buy	+31,030	New	+$23.6K	﹤0.01%	8123

Other funds holding OACCW

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

DAM

Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BGGS

Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group's OACCW Position: Q2 2026 in Review

UBS Group increased its Oaktree Acquisition Corp III Life Sciences Warrant (OACCW) stake by 114% in Q2 2026, buying an estimated $251 and bringing the position to 561 shares worth $528. The position accounts for ﹤0.01% of the portfolio, ranked #9814.

UBS Group first reported a position in OACCW in Q1 2025 and has held it in 6 quarters since. The position peaked at $23.3K in Q1 2025. 27 funds tracked by Wall St. Rank hold OACCW as of Q2 2026.

UBS Group held 561 shares of Oaktree Acquisition Corp III Life Sciences Warrant worth $528 as of Q2 2026.
UBS Group bought 299 Oaktree Acquisition Corp III Life Sciences Warrant shares in Q2 2026, an estimated $251.
Oaktree Acquisition Corp III Life Sciences Warrant made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9814 holding.
UBS Group first reported a position in Oaktree Acquisition Corp III Life Sciences Warrant in Q1 2025 and has held it in 6 quarters since.
UBS Group's Oaktree Acquisition Corp III Life Sciences Warrant position peaked at $23.3K in Q1 2025.
27 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences Warrant as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.